屈螺酮片对患有多囊卵巢综合征的印度女性的影响。
Effects of drospirenone pill in Indian women with polycystic ovary syndrome.
作者信息
Bhattacharya Sudhindra Mohan, Ghosh Mainak, Nandi Nupur
机构信息
Department of Obstetrics and Gynaecology, KPC Medical College, Kolkata, India.
Department of Pharmacology, Calcutta Medical College, Kolkata, India.
出版信息
J Turk Ger Gynecol Assoc. 2011 Sep 1;12(3):144-7. doi: 10.5152/jtgga.2011.34. eCollection 2011.
OBJECTIVE
To study the effects of treatment with a drospirenone pill (DRSP) (with ethinyl oestradiol, EE) in Indian women with polycystic ovary syndrome (PCOS).
MATERIAL AND METHODS
Fifty-one women with PCOS (Androgen excess society criteria, 2006), with preset inclusion-exclusion criteria, treated with a combination of EE 30 mcg and DRSP 3 mg cyclically in the traditional (21+7) regimen, were evaluated at baseline and after six and twelve cycles of treatment. Parameters studied were - body mass index (BMI), abdominal circumference (AC), Ferriman Galwey (FG) score, presence of acne and acanthosis nigricans, serum testosterone, sex hormone binding globulin (SHBG), fasting glucose and fasting insulin levels. Free Androgen Index (FAI) and Glucose: Insulin ratio (G: I) were calculated.
RESULTS
Significant improvements in clinical and biochemical hyperandrogenic parameters were found at the two points of study. There were no significant changes in BMI, AC, incidence of acanthosis, or metabolic parameters studied.
CONCLUSION
EE/DRSP improves hyperandrogenic parameters significantly without affecting the insulin resistance adversely in Indian women with PCOS.
目的
研究屈螺酮片（DRSP）（与炔雌醇，EE合用）治疗印度多囊卵巢综合征（PCOS）女性的效果。
材料与方法
51例符合2006年雄激素过多协会标准的PCOS女性，按照预设的纳入-排除标准，采用传统的（21+7）方案，周期性服用30μg EE与3mg DRSP的复方制剂，在基线、治疗6个周期和12个周期后进行评估。研究的参数包括——体重指数（BMI）、腹围（AC）、费里曼-盖尔维（FG）评分、痤疮和黑棘皮病的存在情况、血清睾酮、性激素结合球蛋白（SHBG）、空腹血糖和空腹胰岛素水平。计算游离雄激素指数（FAI）和血糖：胰岛素比值（G：I）。
结果
在两个研究时间点，临床和生化高雄激素血症参数均有显著改善。BMI、AC、黑棘皮病发病率或所研究的代谢参数均无显著变化。
结论
EE/DRSP可显著改善印度PCOS女性的高雄激素血症参数，且不会对胰岛素抵抗产生不利影响。
Zotero 插件